EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection


British Journal of Nutrition 75(1): 129-138
Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection
The effect of the testosterone derivative oxymetholone alone or in combination with the H1-receptor antagonist ketotifen, which has recently been shown to block tumour necrosis factor alpha (TNF alpha), on weight gain and performance status in human immunodeficiency virus (HIV) patients with chronic cachexia was evaluated in a 30-week prospective pilot study. Thirty patients were randomly assigned to either oxymetholone monotherapy (n 14) or oxymetholone plus ketotifen (n 16). Patients receiving treatment were compared with a group of thirty untreated matched controls, who met the same inclusion criteria. Body weight and the Karnofsky index, which assesses the ability to perform activities of daily life, and several quality-of-life variables were measured to evaluate response to therapy. The average weight gain at peak was 8.2 (SD 6.2) kg (+ 14.5% of body weight at study entry) in the oxymetholone group (P < 0.001), and 6.1 (SD 4.6) kg (+10.9%) in the combination group (P < 0.005), compared with an average weight loss of 1.8 (SD 0.7) kg in the untreated controls. The mean time to peak weight was 19.6 weeks in the monotherapy group and 20.8 weeks in the combination group. The Karnofsky index improved equally in both groups from 56% before to 67% after 20 weeks of treatment (P < 0.05). The quality of life variables (activities of daily life, and appetite/nutrition) improved in 68% (P < 0.05) and 91% (P < 0.01) of the treated patients respectively. Oxymetholone was safe and promoted weight gain in cachectic patients with advanced HIV-1 infection. The addition of ketotifen did not further support weight gain. These results suggest the need for a randomized, double-blind, placebo-controlled multicentre trial.


Accession: 002914220

PMID: 8785183

DOI: 10.1079/bjn19960116



Related references

Oxymetholone promotes significant weight gain in patients with advanced HIV-1 infection. INFECTIOUS DISEASES SOCIETY OF AMERICA [Author], NATIONAL INSTITUTES OF HEALTH [Author], CENTERS FOR DISEASE CONTROL AND PREVENTION [Author] 3rd Conference on retroviruses and opportunistic infections : 126, 1996

Body weight as essential data in the management of patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome. American Journal of Clinical Nutrition 58(3): 317-318, 1993

Atypically severe but treatable Clostridium difficile infection in patients with advanced human immunodeficiency virus infection A study with follow-up of seven consecutive patients admitted from 1986 to 1992. Gastroenterology 104(4 SUPPL ): A675, 1993

Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infection: a study of seven consecutive patients admitted from 1986 to 1992 to a university teaching hospital. American Journal of Gastroenterology 88(6): 891-897, 1993

Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 324(5): 289-294, 1991

Human immunodeficiency virus-associated eosinophilic folliculitis. A unique dermatosis associated with advanced human immunodeficiency virus infection. Archives of Dermatology 127(2): 206-209, 1991

Bacteremia and fungemia in patients with advanced human immunodeficiency virus (HIV) infection in Taiwan. Journal of the Formosan Medical Association 97(10): 690-697, 1998

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 339(6): 405-406, 1998

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 332(11): 693-699, 1995

Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. Journal of Infectious Diseases 168(5): 1264-1268, 1993